The Centre for Commercialization of Cancer Immunotherapy (C3i) will accelerate discovery, commercialization and access to innovative cancer immunotherapies for patients. Operating out of the Hôpital Maisonneuve-Rosemont installation of the Integrated University Center of East Montreal (CIUSS de l’Est-de-l’île-de-Montréal), the centre will offer an integrated structure for the development, translation and commercialization of these groundbreaking therapies. C3i will combine three interacting units that will provide patients with cutting edge biomarker and diagnostic tests, good manufacturing practices standards and rapid access to clinical trials and regulatory support to bring effective and affordable remedies more rapidly to Canadians and the world. This will strengthen Canada’s position as a leader in the emerging field of cancer immunotherapy.

Immunotherapy is a rapidly emerging practice that harnesses the power of the immune system to combat cancer. It could revolutionize cancer care by developing nontoxic, highly efficient and decisive cures that do not rely on chemotherapeutic agents, thus improving patients’ quality of life and reducing healthcare costs. These treatments could be used in 60% of advanced cancer patients by 2025. Canada needs greater capacity to translate these therapies into patient care, and to help Canadian companies compete in a potential $40 billion market.

Contact info:

  CCRM, a Canadian not-for-profit funded by the Government of Canada, the Province of Ontario, and leading academic and industry partners, supports the development of regenerative medicines and associated enabling technologies, with a specific focus on cell and gene therapy. A network of academic researchers, leading companies, strategic investors and entrepreneurs, CCRM aims to accelerate the translation of scientific discovery into marketable products for patients with specialized teams funding, and infrastructure. CCRM sources and evaluates intellectual property from around the globe, offers various consulting services, conducts development projects with partners, and establishes new companies built around strategic bundles of intellectual property. CCRM has a 40,000 square foot space dedicated to advanced cell manufacturing that includes a fully resourced development facility used to both evaluate and advance technologies. CCRM is hosted by the University of Toronto and was launched in Toronto’s Discovery District on June 14, 2011.

Visit us at

 Contact Info: Spencer Hoover, Development Manager

Gold Sponsors

When science and passion connect, innovation happens. The oncology community shares a common mission: to transform the way patients live with cancer and related diseases. At Novartis Oncology, we are passionate about the discovery and development of innovative medicines. We seek to provide a broad range of new therapies as well as practical solutions to advance the care of patients.

With over 9000 Oncology employees worldwide operating in 85 countries, Novartis Oncology has a truly global reach. We have the advantage of extraordinarily talented and globally diverse employees who, through shared goals and different perspectives, are dedicated to transforming the lives of patients living with cancer around the world. We have developed eight new practice-changing medicines in the past decade, addressing unmet medical needs in patients worldwide. Our broad pipeline includes over 25 new molecular entities in development, targeting key molecular pathways in cancer biology.

Visit us at

  STEMCELL Technologies provides reagents to take cell therapy research from bench to bedside with T cell isolation, activation and expansion products. STEMCELL’s collaboration with GE Healthcare aims to give researchers the confidence of a path to the clinic with cGMP-grade T cell reagents. Learn more at

Silver sponsors


Transporting innovation

At World Courier, we move innovation forward. Whether designing and executing world-class logistics processes for the biopharmaceutical industry, or providing emergency logistical support for other key industries, we’ve built our reputation on half a century of proven reliability and flawless execution.


Committed to improving the lives of patients worldwide

At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients. Our vision as a company is to build a major global biopharmaceutical corporation while focusing on the discovery, the development, and the commercialization of products for the treatment of cancer and other severe, immune, inflammatory conditions.

“At Celgene, we seek to deliver truly innovative and life-changing drugs for our patients.”

There are more than 300 clinical trials at major medical centers using compounds from Celgene. Investigational compounds are being studied for patients with incurable hematological and solid tumor cancers, including multiple myeloma, myelodysplastic syndromes, chronic lymphocytic leukemia (CLL), non-Hodgkin’s lymphoma (NHL), triple-negative breast cancer and pancreatic cancer. As committed as we are to clinical accomplishment, we are equally committed to patient support, which is a guiding principle at Celgene. We believe all who can benefit from our discoveries should have the opportunity to do so. Celgene puts patients first with industry-leading programs that provide information, support and access to our innovative therapies.

Bronze Sponsors

GE Healthcare Life Sciences provides solutions for a wide range of applications, including basic research of cells and proteins, drug discovery research, and tools to support large-scale manufacturing of biopharmaceuticals. Our Cell Therapy business enables customers from pharmaceutical manufacturing as part of our Cell Processing segment, to clinicians and technicians in our Cell Banking and Point of Care segments to help meet immediate needs, as well as innovative production capabilities for the future.


Contact: Barbara Leone, Account Manager,


Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes innovative medicines in areas of unmet medical need. The company strives to transform and simplify care for people with life-threatening illnesses around the world. Gilead has operations in more than 35 countries worldwide, with headquarters in Foster City, California. Gilead Sciences Canada, Inc. is the Canadian affiliate of Gilead Sciences, Inc., and was established in Mississauga, Ontario in 2006.

For more information on Gilead Sciences, please visit the company’s website at


Your valuable material arrives on time, in perfect condition.

Medair facilitates the worldwide express transport of time critical Pharmaceutical and Biological material. Our established capabilities in major marketplaces throughout the world allow us to focus on ensuring that your shipment is moved both quickly and efficiently, arriving in perfect condition. Every Medair shipment is individually handled, routed and monitored through to an exact timed delivery, virtually anywhere in the world.

Medair is an ISO:9001 Certified Company

  Roche Diagnostics, a division of the Swiss company Hoffmann-La Roche Ltd., is the world leader in in vitro diagnostics. In Canada, Roche Diagnostics is the leader of its sector. Roche Diagnostics offers a uniquely broad product portfolio and innovative solutions to researchers, physicians, patients, hospitals and laboratories in the fields of diabetes care and anticoagulation therapy, molecular biology, diagnostic in-situ, clinical chemistry, immunology and life sciences. Roche Canada has its Diagnostics head office in Laval and its Pharmaceutical head office in Mississauga, Ontario.

Visit us at


  We are building a fully integrated biopharmaceutical company to maximize the potential of ATIR, our proprietary cell-based immunotherapy platform. Our lead program, ATIR101, has the potential to help patients in urgent need of stem cell transplants for blood cancers. ATIR101 is a patient-specific T-cell product designed to be delivered following a haploidentical hematopoietic stem cell transplant, or HSCT, in order to support the patient’s newly transplanted immune system before it becomes fully functional. In ATIR, T-cells causing Graft-versus-Host-Disease (GVHD) have been depleted, while T-cells protective against tumor cells and infections have been retained. This provides physicians with the opportunity to infuse potent T-cells with minimal risk of causing potential lethal severe GVHD. ATIR, therefore, addresses one of the biggest challenges of using haploidentical family members as stem cell donors for those patients that would otherwise not find a matching donor in time. ATIR101 has completed phase 2 clinical trials and is currently enrolling a global phase 3 program. A market authorization application based on the phase 2 data for ATIR101 is currently under review by the EMA, with a decision expected in 2019. Kiadis Pharma is committed to developing innovative and potentially life-saving therapies for patients with late-stage blood cancers, who are in need of a transplant, an area of significant medical need.

Created in 2009, the ThéCell Network has now more than one hundred full members. It strives to facilitate phase I and II clinical studies in order to accelerate the availability of the technologies developed in cell, tissue and gene therapy for the general population. The cell and tissue therapy platforms of the universities throughout the province of Quebec and their partners are supported in their clinical trial development.

ThéCell is a thematic network supported by the Fonds de recherche du Québec–Santé provides leverage and serves as catalyst for the utilization of the infrastructures and the training of highly qualified personnel in the field of cell, tissue and gene therapy.


BioCanRx was announced as a Network of Centres of Excellence on December 15, 2014, with a total of $60 million in funding and commitments from the NCE Program and more than 25 partners.


Its mandate it to be a global leader in the translation, manufacture and adoption of innovative cancer biotherapeutics for the benefit of all cancer patients by working in partnership with academia, industry, government, patients, charities and NGOs to identify, develop and de-risk promising cancer biotherapies.

BioCanRx is committed to excellent science in a field with great promise. Its focus is on translating this science into what we hope will be significantly better therapies for cancer patients. BioCanRx funds translational projects to accelerate the development of these therapies from the laboratory to the clinic. To that end, it has a goal of advancing four new cancer biotherapies into Canadian-led clinical trials by 2020.

Visit BioCanRx website


From biotech concept through to design, biotech validation and production across all biotech applications, we can help you adapt to changing market conditions with innovative technologies and solutions.

Whether that means quickly developing a process for a new drug, helping you ensure regulatory compliance, or making existing processes easier, faster and better, we are ready to work with you to address your biotech needs.


Eppendorf is a leading life science company that develops and sells instruments, consumables, and services for liquid-, sample-, and cell handling in laboratories worldwide. Its product range includes pipettes and automated pipetting systems, dispensers, centrifuges, mixers, spectrometers, and DNA amplification equipment as well as ultra-low temperature freezers, fermentors, bioreactors, CO2 incubators, shakers, and cell manipulation systems. Consumables such as pipette tips, test tubes, microtiter plates, and single-use bioreactor vessels complement the range of highest-quality premium products.